← FDA DRUG APPROVALS

FDA ANDA · ANDA075074

ETODOLAC

Sponsor: TARO PHARM INDS

APPLICATION
ANDA075074
TYPE
ANDA
ORIGINAL APPROVAL
1998-03-11
LATEST ACTION
2024-11-21
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

ETODOLACPrescription
ETODOLAC 400MG · TABLET · ORAL
ETODOLACPrescription
ETODOLAC 500MG · TABLET · ORAL

Approval history

2024-11-21Labeling · Supplement 33 · standardAP
2021-04-28Labeling · Supplement 26 · standardAP
2016-05-09Labeling · Supplement 18 · standardAP
2009-01-14Labeling · Supplement 13AP
2006-11-17Labeling · Supplement 12AP
2006-03-02Labeling · Supplement 10AP
2002-09-11Manufacturing (CMC) · Supplement 5AP
2002-09-11Manufacturing (CMC) · Supplement 6AP
2002-07-18Manufacturing (CMC) · Supplement 3AP
2002-05-10Manufacturing (CMC) · Supplement 7AP
2000-04-25Manufacturing (CMC) · Supplement 1AP
2000-04-25Labeling · Supplement 2AP
1998-03-11OriginalReviewAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →